Enliven Therapeutics
Quarterly Financials
| Values in thousands | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -46 | -81 | -74 | |
EBITDA | -34,239 | -20,086 | -28,503 | -31,619 |
EBIT | -34,285 | -20,148 | -28,584 | -31,693 |
Net Income | -29,667 | -20,148 | -25,335 | -28,544 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -15,838 | -13,278 | -17,196 | -24,147 |
Cash | 98,896 | 101,732 | 119,437 | 101,705 |
Basic Shares | 56,664 | 62,093 | 52,105 | 50,051 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -263 | -317 | -297 | -622 |
EBITDA | -119,395 | -104,237 | -83,232 | -38,576 |
EBIT | -119,658 | -104,554 | -83,529 | -38,791 |
Net Income | -103,694 | -89,024 | -71,584 | -37,662 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -70,459 | -73,236 | -61,418 | -32,689 |
Cash | 98,896 | 124,117 | 100,141 | 75,536 |
Basic Shares | 56,664 | 47,073 | 35,546 | 6,249 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-12-31 | -$0.48 |
2025-09-30 | -$0.32 |
2025-06-30 | -$0.49 |
2025-03-31 | -$0.57 |